Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry
| Autor: | Maria Papaioannou, Eleftheria Hatzimichael, Menelaos-Konstantinos Papoutselis, Alexandra Kourakli, George Vassilopoulos, Panayiotis Panayiotidis, Vasiliki Pappa, Helen A. Papadaki, Eleni Solomou, Panagiotis Zikos, Argiris Symeonidis, Nora-Athina Viniou, Sotirios G. Papageorgiou, Georgios Kyriakakis, Maria Dimou, Achilles Anagnostopoulos, Panagiotis T. Diamantopoulos, Athanasios Galanopoulos, Aekaterini Megalakaki, Panagiotis Repousis, Ioannis Kotsianidis, Charalampos Pontikoglou, Maria Kotsopoulou, Dimitrios Tsokanas |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Percentile Treatment response Multivariate analysis 03 medical and health sciences 0302 clinical medicine Stable Disease Internal medicine Long term survival medicine Humans In patient Registries Aged Aged 80 and over business.industry Hematology Middle Aged Prognosis Oncology Quartile International Prognostic Scoring System Myelodysplastic Syndromes 030220 oncology & carcinogenesis Azacitidine Female business 030215 immunology |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 20:114-121 |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2019.09.614 |
| Popis: | Background Hypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible treatment goal. Patients and Methods We analyzed data from patients with MDS treated with 5-azacytidine recorded in the Hellenic 5-azacytidine registry. We divided patients, on the basis of their survival after 5-azacytidine initiation (OST), in groups of long-term survivors (Q3 and P90 group with OST above the third quartile and the 90th percentile of the whole group, respectively) and short-term survivors comprising the remaining patients, and compared the characteristics between the groups. The study included 626 patients, 157 in the Q3 group and 63 in the P90 group. Results Categorization per the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), and World Health Organization–based prognostic scoring system (WPSS) was found to predict long-term survival, while multivariate analysis revealed that response to 5-azacytidine was the strongest predictor of long-term survival. Nevertheless, patients with hematologic improvement (HI) and stable disease (SD) were equally distributed in the groups of short- and long-term survival. Conclusion SD should not be considered a poor treatment response and should not be grouped with failure, while HI offers similar prognosis to SD and thus should not be grouped with complete and partial remission. Patients with SD should continue treatment with 5-azacytidine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect